Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 8/20 | 0.61 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.61 |
| ▸ | PNMT | P11086 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.59 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.59 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.57 |
| ▸ | HTR2A | P28223 | 3/20 | 0.55 |
| ▸ | HTR2B | P41595 | 3/20 | 0.55 |
| ▸ | HTR2C | P28335 | 2/20 | 0.55 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | DRD1 | P21728 | 1/20 | 0.53 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.53 |
| ▸ | MIF | P14174 | 1/20 | 0.53 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gepefrine SCHEMBL265538 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL2562808 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL30011768 | 1.00 | TAAR1 (0.61) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL2903935 | 0.98 | TAAR1 (0.59) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL2903938 | 0.98 | TAAR1 (0.59) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL6016854 | 0.87 | LMNA (0.64) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| Gepefrine SCHEMBL5599678 | 0.87 | LMNA (0.64) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| SCHEMBL4692874 | 0.86 | ADRB1 (0.53) | TAAR1SLC6A2PNMTMAOASLC6A4 | |
| SCHEMBL3067767 | 0.85 | ENPP2 (0.59) | TAAR1ENPP2HTR2AHTR2BDRD2 | |
| SCHEMBL4531632 | 0.85 | ALOX15 (0.55) | TAAR1SLC6A2SLC6A3ENPP2HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 801 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2649989-B1 | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof | UNIV KING SAUD (SA) | 2017-10-18 | — | — | EP | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| EP-2649989-A1 | Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof | King Saud University (SA) | 2013-10-16 | — | — | EP | claimed |
| EP-2560634-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | Piramal Enterprises Limited (IN) | 2013-02-27 | — | — | EP | claimed |
| US-8163806-B2 | Controlled release of biologically active compounds from multi-armed oligomers | BEZWADA BIOMEDICAL, LLC (US) | 2012-04-24 | — | — | US | claimed |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | BEZWADA BIOMEDICAL, LLC (US) | 2012-01-12 | — | — | US | claimed |
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | US | claimed |
| WO-2011132171-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | PIRAMAL LIFE SCIENCES LIMITED (IN) | 2011-10-27 | — | — | WO | claimed |
| JP-4763957-B2 | — | — | 2011-08-31 | — | — | JP | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-1211164-C | Medium milling | RTP PHARMA INC (CA) | 2005-07-20 | — | — | CN | claimed |
| CN-1441704-A | Media milling | RTP PHARMA INC (CA) | 2003-09-10 | — | — | CN | claimed |
| US-6604698-B2 | Media milling | SKYEPHARMA CANADA, INC. (CA) | 2003-08-12 | — | — | US | claimed |
| WO-2003024456-A1 | METHODS FOR TREATING AND PREVENTING MIGRAINES | EISAI CO., LTD. (JP) | 2003-03-27 | — | — | WO | claimed |
| EP-1280604-A1 | MEDIA MILLING | RTP Pharma Inc. (US) | 2003-02-05 | — | — | EP | claimed |
| US-20020003179-A1 | Media milling | SKYEPHARMA AG (CH) | 2002-01-10 | — | — | US | claimed |
| WO-2001085345-A1 | MEDIA MILLING | RTP PHARMA INC. (US) | 2001-11-15 | — | — | WO | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263526-A1 | Nitric Oxide Releasing Prodrugs of Therapeutic Agents | NOS2, NOS1, NOS3 | TAAR1 592/4885SLC6A2 397/4885PNMT 425/4885 |
| US-20120010284-A1 | CONTROLLED RELEASE OF BIOLOGICALLY ACTIVE COMPOUNDS FROM MULTI-ARMED OLIGOMERS | MME, AADAC, LGMN | TAAR1 2757/4885SLC6A2 4441/4885PNMT 1224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.